Nitric Oxide Modulation Of The Basal Ganglia Circuitry: Therapeutic Implication For Parkinson's Disease And Other Motor Disorders

Giuseppe Di Giovanni, Arcangelo Benigno, Alessandro Pitruzzella, Salvatore Galati, Alessandro Pitruzzella, Mario Valentino, Massimo Pierucci, Vincenzo Di Matteo, Richard Muscat, Arcangelo Benigno, Giuseppe Di Giovanni

Risultato della ricerca: Article

25 Citazioni (Scopus)

Abstract

Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. For example, inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating Parkinson's disease and related disorders.
Lingua originaleEnglish
pagine (da-a)777-791
Numero di pagine15
RivistaCNS & NEUROLOGICAL DISORDERS. DRUG TARGETS
Volume10
Stato di pubblicazionePublished - 2011

Fingerprint

Basal Ganglia
Parkinson Disease
Nitric Oxide
Therapeutics
Subthalamus
Pharmacology
Guanosine Monophosphate
Corpus Striatum
Globus Pallidus
Dopaminergic Neurons
Dyskinesias
Phosphoric Diester Hydrolases
Movement Disorders
Levodopa
Substantia Nigra
Nitric Oxide Synthase
Motor Disorders
Signal Transduction
Animal Models
Neurons

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Pharmacology

Cita questo

Nitric Oxide Modulation Of The Basal Ganglia Circuitry: Therapeutic Implication For Parkinson's Disease And Other Motor Disorders. / Di Giovanni, Giuseppe; Benigno, Arcangelo; Pitruzzella, Alessandro; Galati, Salvatore; Pitruzzella, Alessandro; Valentino, Mario; Pierucci, Massimo; Di Matteo, Vincenzo; Muscat, Richard; Benigno, Arcangelo; Di Giovanni, Giuseppe.

In: CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS, Vol. 10, 2011, pag. 777-791.

Risultato della ricerca: Article

Di Giovanni, Giuseppe ; Benigno, Arcangelo ; Pitruzzella, Alessandro ; Galati, Salvatore ; Pitruzzella, Alessandro ; Valentino, Mario ; Pierucci, Massimo ; Di Matteo, Vincenzo ; Muscat, Richard ; Benigno, Arcangelo ; Di Giovanni, Giuseppe. / Nitric Oxide Modulation Of The Basal Ganglia Circuitry: Therapeutic Implication For Parkinson's Disease And Other Motor Disorders. In: CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS. 2011 ; Vol. 10. pagg. 777-791.
@article{cfa99ef6ed16490f98c8f37453af2336,
title = "Nitric Oxide Modulation Of The Basal Ganglia Circuitry: Therapeutic Implication For Parkinson's Disease And Other Motor Disorders",
abstract = "Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. For example, inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating Parkinson's disease and related disorders.",
keywords = "BASAL GANGLIA, NITRIC OXIDE",
author = "{Di Giovanni}, Giuseppe and Arcangelo Benigno and Alessandro Pitruzzella and Salvatore Galati and Alessandro Pitruzzella and Mario Valentino and Massimo Pierucci and {Di Matteo}, Vincenzo and Richard Muscat and Arcangelo Benigno and {Di Giovanni}, Giuseppe",
year = "2011",
language = "English",
volume = "10",
pages = "777--791",
journal = "CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS",
issn = "1871-5273",

}

TY - JOUR

T1 - Nitric Oxide Modulation Of The Basal Ganglia Circuitry: Therapeutic Implication For Parkinson's Disease And Other Motor Disorders

AU - Di Giovanni, Giuseppe

AU - Benigno, Arcangelo

AU - Pitruzzella, Alessandro

AU - Galati, Salvatore

AU - Pitruzzella, Alessandro

AU - Valentino, Mario

AU - Pierucci, Massimo

AU - Di Matteo, Vincenzo

AU - Muscat, Richard

AU - Benigno, Arcangelo

AU - Di Giovanni, Giuseppe

PY - 2011

Y1 - 2011

N2 - Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. For example, inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating Parkinson's disease and related disorders.

AB - Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. For example, inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating Parkinson's disease and related disorders.

KW - BASAL GANGLIA

KW - NITRIC OXIDE

UR - http://hdl.handle.net/10447/60777

UR - http://www.ncbi.nlm.nih.gov/pubmed/21999732

M3 - Article

VL - 10

SP - 777

EP - 791

JO - CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS

JF - CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS

SN - 1871-5273

ER -